Cerus Corporation CERS
Cerus Corporation (Nasdaq: CERS) is a hematology drug developer. Its lead program, INTERCEPT Blood System for red blood cells, is in Phase 3 for Pathogen reduction in red blood cells to prevent transfusion-transmitted infections. Its next catalyst on record is Lyo-Cryo: Phase III clinical study completion under DoD contract (2028).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: Lyo-Cryo — Phase III clinical study completion under DoD contract (2028). 4 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| INTERCEPT Blood System for Platelets | Pathogen reduction in platelets | small molecule | Approved |
| INTERCEPT Blood System for Plasma | Pathogen reduction in plasma | small molecule | Approved |
| INTERCEPT Blood System for Cryoprecipitation (IFC) | Treatment of bleeding associated with fibrinogen deficiency | protein/peptide | Approved |
| INTERCEPT Blood System for red blood cells | Pathogen reduction in red blood cells | small molecule | Phase 3 |
| Lyo-Cryo (lyophilized cryoprecipitate) | Bleeding due to trauma | protein/peptide | Phase 3 |
Recent results and decisions
- Nov 2, 2026positive Cerus announced positive topline Phase 3 RedeS results for the INTERCEPT Blood System for red blood cells.
Announced positive topline results from the Phase 3 RedeS trial of the INTERCEPT Blood System for red blood cells.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 hematology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.